Recent News
It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.Read Article
How many CAR-T’s do we need to test drive?
CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.
Read Article
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
https://t.co/ir9pdwBnH4 https://t.co/yjjgcA2TRv
Dr. John Cush @RheumNow ( View Tweet)
Renal Biopsies in SLE
Dr. Andrea Fava reporting from EULAR 2026 in London.
https://t.co/naCyEAutbb https://t.co/XgdiXY3hiO
Dr. John Cush @RheumNow ( View Tweet)
When Patients with RA Choose Their Treatment, Outcomes Are Better — Here's the Data
Dr. Aurelie Najm discusses abstract OP0204 presented in London at the EULAR 2026 Congress.
https://t.co/hHQFffTXH0 https://t.co/tXv0SnGBz1
Dr. John Cush @RheumNow ( View Tweet)
PsA Topic Panel: EULAR 2026
Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. Abstracts discuss: OP0187, OP069, LB0001, POS0668, OP071
https://t.co/S7Fz5YR3V0 https://t.co/treaJ1OzwB
Dr. John Cush @RheumNow ( View Tweet)
LLMs in SLE: From Patient Education to Clinical Decision Support
The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical settings. Two EULAR 2026 abstracts highlight the evolving role of LLMs across this spectrum, from patient-facing education to diagnostic reasoning.
Read Article
NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.
Read Article
Obinutuzumab drives histologic remission in lupus nephritis
At #EULAR2026, new data from the phase III REGENCY trial add to the case for obinutuzumab in lupus nephritis. Investigators report deep intrarenal B-cell depletion and significantly higher rates of histological https://t.co/AlJ5I8s2JE
Dr. John Cush @RheumNow ( View Tweet)
RA-ILD in the Age of Treat-to-Target: Put the Probe on the Chest
RA inflammation may be under control, but RA-associated ILD remains a major challenge. At #EULAR2026, experts highlighted that ILD is one of the few RA outcomes not improving in the biologic era. Three new https://t.co/FXCKlyKYfr
Dr. John Cush @RheumNow ( View Tweet)
Join Dr. Jack Cush and Dr. Arthur Kavanaugh live for the EULAR 2026 Rheumatology Round-Up on Friday, June 12 at 1:00 PM ET as they break down the meeting's biggest stories, practice-changing data, and key clinical takeaways.
From late-breaking research and emerging therapies to https://t.co/Tl9U6F14OM
Dr. John Cush @RheumNow ( View Tweet)
Immune Dimming or Immune Reset in RA: How Far Should We Go?
CD19 CAR T-cell therapy has moved from oncology to autoimmune disease after SLE reports of sustained drug-free remission suggesting an immune reset. This raises whether profound depletion is needed or if milder https://t.co/WONQmhs86j
Dr. John Cush @RheumNow ( View Tweet)
New: Classification Criteria and Recommendations in SpA
ASAS and SPARTAN have updated their key classification criteria for axSpA. EULAR has also recently revised its recommendations on the role of imaging in the diagnosis and clinical management of SpA. https://t.co/YOWfwTkbqp
Dr. John Cush @RheumNow ( View Tweet)
Synovio-entheseal inflammation and the tipping point from PsO to PsA
Psoriatic arthritis develops in approximately 20 to 30 per cent of patients with psoriasis, yet predicting which patients will make the transition and when, has remained one of the most clinically challenging questions in rheumatology. A study presented at EULAR 2026 provides the most granular ultrasound characterisation yet of the journey from psoriasis, through subclinical disease, to early clinical PsA. The study identifies the specific
Read Article
Improving Referrals for Inflammatory Arthritis
Dr. Antoni Chan discusses abstracts POS1284 and POS0784 presented at EULAR 2026 in London
https://t.co/p1iT8yPNzF https://t.co/gEyuEwW4aj
Dr. John Cush @RheumNow ( View Tweet)
Gout and ULT Withdrawal -- The GO TEST FINALE Trial
Professor Noortje van Herwaarden reviews abstract OP001 at EULAR 2026 in London
https://t.co/d8U1168SRn https://t.co/hP0EUrciTu
Dr. John Cush @RheumNow ( View Tweet)
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
https://t.co/TSnVVOpF75 https://t.co/EFD0WKRpF4
Dr. John Cush @RheumNow ( View Tweet)
Exploring Idiopathic Myopathies
#EULAR2026: Idiopathic inflammatory myopathies (IIM) are a diverse group of autoimmune diseases with significant morbidity. While EULAR/ACR classification criteria were established in 2017, updated real-world data and better tools to assess https://t.co/CbUWodWT7z
Dr. John Cush @RheumNow ( View Tweet)
What’s New in Psoriatic Arthritis: A Whirlwind Tour
At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/IzsSzx6Pc9
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
RheumNow EULAR 2026 Rheumatology Round Up
EULAR 2026 RA Topic Panel
CAR-T Topic Panel EULAR 2026
EULAR 2026 PsA Update What's Changing in P
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
